

ARTICLE

Molecular characterisation of patients with subtelomeric 22q abnormalities using chromosome specific array-based comparative genomic hybridisation

David A Koolen¹, William Reardon², Elisabeth M Rosser³, Didier Lacombe⁴, Jane A Hurst⁵, Caroline J Law⁶, Ernie MHF Bongers¹, Conny M van Ravenswaaij-Arts¹, Martijn AR Leisink⁷, Ad Geurts van Kessel¹, Joris A Veltman¹ and Bert BA de Vries^{*,1}

¹Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; ²National Centre for Medical Genetics, Our Lady's Hospital for Sick Children, Crumlin, Dublin, Ireland; ³Department of Clinical Genetics, Institute of Child Health, London, UK; ⁴Department of Medical Genetics, CHU Pellegrin, Bordeaux, France; ⁵Department of Clinical Genetics, The Churchill Hospital, Oxford, UK; ⁶Wessex Regional Genetics Service, The Princess Anne Hospital, Southampton, UK; ⁷Department of Medical Physics and Biophysics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

The 22q13 deletion syndrome is associated with global developmental delay, absent or delayed speech, and generalised hypotonia. In this study, the size and nature of 22q13 deletions ($n = 9$) were studied in detail by high-resolution chromosome specific array-based comparative genomic hybridisation (array CGH). The deletion sizes varied considerably between the different patients, that is, the largest deletion spanning 8.4 Mb with the breakpoint mapping to 22q13.2 and the smallest deletion spanning 3.3 Mb with the breakpoint mapping to 22q13.31. In one case, a unique subtelomeric 3.9 Mb deletion associated with a 2.0 Mb duplication of 22q13 was observed, adding to a growing number of similar cases identified for other chromosome ends. Remarkably, this patient had signs suggestive of retinitis pigmentosa, which has never been reported before in the 22q13 deletion syndrome. The identification of two pairs of recurrent proximal breakpoints on 22q13 suggests that these specific regions may be prone to recombination, due to yet unknown genome architectural features. In addition to the copy number changes on 22q13, a duplication of ~330 kb on 22q11.1 was observed and shown to be a genetic large-scale copy number variation without clinical consequences. The current study failed to reveal relationships between the clinical features and the deletion sizes. Global developmental delay and absent or severely delayed speech were observed in all patients, whereas hypotonia was present in 89% of the cases (8/9). This study underscores the utility of array CGH for characterising the size and nature of subtelomeric deletions, such as monosomy 22q13, and underlines the considerable variability in deletion size in the 22q13 deletion syndrome regardless of the clinical phenotype.

European Journal of Human Genetics (2005) 13, 1019–1024. doi:10.1038/sj.ejhg.5201456;
published online 29 June 2005

Keywords: 22q13 deletion syndrome; array CGH; mental retardation; submicroscopic; subtelomeric

*Correspondence: Dr BBA de Vries, Department of Human Genetics, 417, Radboud University Nijmegen Medical Centre, PO Box 9101, Nijmegen 6500 HB, The Netherlands. Tel: +31 24 361 3946; Fax: +31 24 366 8753;

E-mail: b.devries@antrg.umcn.nl

Received 25 February 2005; revised 9 May 2005; accepted 19 May 2005; published online 29 June 2005

Introduction

Subtelomeric deletions are a common cause of mental retardation.^{1,2} In recent years, screening of subtelomeres for copy number changes in mentally retarded patients has resulted in the recognition of new distinct clinical entities, based on monosomy 1q, 2q, 9q, 14q, and 22q (reviewed in Vries *et al*¹). The latter entity is also referred to as the 22q13 deletion syndrome, of which to date at least 100 cases have been reported.^{3–6} Common features associated with this syndrome are mild-to-severe global developmental delay, absent or delayed speech, generalised hypotonia, and minor anomalies including dolichocephaly, ptosis, abnormal ears, relatively large hands, and dysplastic toenails.⁵

Here we describe a series of nine patients with monosomy 22q13 in which the size and the nature of the chromosome 22 deletions were studied in detail by high-resolution chromosome-specific array-based comparative genomic hybridisation (array CGH).⁷

Materials and methods

Patients and DNA samples

In total, nine patients with subtelomeric deletions of 22q13 were included in this study. Three cases were previously published (case 2,⁸ case 7⁹ and case 9¹⁰). DNA samples of the patients were derived from different clinical centres in France, Ireland, the United Kingdom, and the Netherlands (Nijmegen). Clinical information on the patients was obtained from the referring physician. DNA samples of all patients were analysed using array CGH. In one patient (case 3), the 22qter deletion was initially identified by routine chromosome analysis at a 550-band level and confirmed by fluorescence *in situ* hybridisation (FISH) [46, XY, del(22)(q13.2).ish del(22)(TUPLE +, ARSA-)]. Another deletion (case 4) resulted from a *de novo* translocation [46, XY, der(22)t(14;22)(q32.33;q13.31)pat. ish der(22)(N85A3-)], whereas the remaining cases were initially identified by FISH, using the following probes: N85A3 (cases 1–2, 5), ARSA (cases 6–8), D22S163 (case 8), or STS WI-941 and D22S39 (case 9).

Array-based comparative genomic hybridisation

High-resolution chromosome 22 array CGH was performed. The microarray consisted of 350 positionally selected chromosome 22 BAC clones (BACPAC Resources), together with 1532 control clones located on other chromosomes. The chromosome 22-specific clones covered the long arm of chromosome 22 (35.1 Mb) with an average spacing of one clone per 100 kb. However, the actual resolution may be less in repeat dense regions. The average clone-insert size was 168 kb, resulting in a 1.7-fold coverage of the long arm of chromosome 22. DOP-PCR products of the BAC clones were spotted in six-fold onto CMT-GAPS-coated glass slides (Ultragaps, Corning) using an OmniGrid 100 arrayer (Genomic Solutions). All steps in the labelling,

hybridisation, and data-analysis procedure were performed as described previously.¹¹ In brief, equal amounts of patient and reference genomic DNAs were labelled by random priming with Cy3-dUTP or Cy5-dUTP (Amersham Biosciences). Labelled test- and reference DNAs were mixed with Cot-1 DNA (Roche), coprecipitated and resuspended in a hybridisation solution. After denaturation of probe and target DNA, hybridisation and posthybridisation washing procedures were performed using a GeneTac Hybridisation Station (Genomic Solutions), according to the instructions of the manufacturer. Fluorescence intensity images were acquired using an Affymetrix 428 scanner (Affymetrix), and analysed by Genepix Pro 5.1 (Axon Instruments).

Statistical data analysis

Data normalisation was performed by applying Lowess curve fitting with a smoothing factor of 0.3 as described by Vissers *et al*¹¹. Copy number alterations were identified by using a Hidden Markov Model algorithm. Three hidden states represent normal, loss, and gain conditions. The probability to observe a log ratio given its hidden state is modelled by a Gaussian with SD 0.25 and mean 0, -0.4 and 0.4, respectively. The hidden state of adjacent clones is correlated with respect to their distance. The thresholded marginal probability of a clone's hidden state determines if it is normal, a loss or gain. In order to discriminate between causative aberrations and large-scale copy number variations (LCV) we used a data set of 72 normal individuals. The control population was tested by a genome-wide 32,477 clone BAC array which included the same clones as used for the chromosome 22 array.

Results

Seven patients with a submicroscopic 22qter deletion, one patient with an unbalanced translocation and one patient with a microscopically visible 22qter deletion were studied. In Table 1, the main characteristics of the patients are summarised. In addition, minor facial dysmorphisms were noted (Figure 1). High-resolution chromosome 22-specific array CGH confirmed the known copy number changes in all cases and delineated the specific aberrations in detail. Figure 2 shows two examples of chromosome 22 array CGH profiles. All deletions analysed included the most telomeric clones. Interstitial deletions in the subtelomeric region of the long arm of chromosome 22 were not observed. The deletion sizes identified in this study varied considerably between the different patients, that is, the largest deletion spanning 8.4 Mb with breakpoint mapping to 22q13.2qter (68 clones, case 1) and the smallest deletion spanning 3.3 Mb with breakpoints mapping to 22q13.31qter (27 clones, case 9) (Figure 3). Identical proximal breakpoints were localised in cases 2 and 3 (between RP11-786O06 and RP11-236I15) and cases 5 and 6 (between RP11-766K21 and

Table 1 Main characteristics of 22q13 deletion cases presented in this study

Patients	1	2 ⁸	3	4 ^a	5	6	7 ⁹	8	9 ¹⁰
Deletion size (Mb)	8.4	7.7	7.7	6.6	5.9	5.9	5.0	3.9	3.3
Duplication size (Mb)	–	–	–	–	–	–	–	2.0	–
<i>Clinical characteristics</i>									
Sex	F	M	M	M	F	F	M	F	F
Global developmental delay	+	+	+	+	+	+	+	+	+
Normal to accelerated growth	+	+	+	+	+	+	+	–	+
Absent/severely delayed speech	+	+	+	+	+	+	+	+	+
Hypotonia	+	+	+	+	+	+	+	–	+
Chewing behaviour	+	–	–	–	–	–	+	–	–
Dolichocephaly	–	–	–	–	–	–	–	–	–
Ptosis	–	–	–	–	–	–	–	–	–
Prominent/dysplastic ears	+	+	+	+	+	+	+	+	–
Prominent/pointed chin	+	–	–	+	+	+	+	–	–
Relatively large, fleshy hands	+	–	–	–	+	+	+	+	–
Abnormal toenail growth	+	+	+	–	+	–	+	–	–

F, female; M, male; +, feature present; –, feature absent.

^a46,XY,der(22)t(14;22).



Figure 1 Patients with 22q13 deletion syndrome. Note the known facial features of the 22q13 deletion syndrome, prominent dysplastic ears (visible in cases 1, 2, 4 and 5), and a prominent/ pointed chin (cases 1 and 4–7).

RP11-49A20), resulting in deletion sizes of 7.7 and 5.9 Mb, respectively. In case 3, a del(22)(q13.2qter) was originally identified by routine chromosome analysis. Array CGH analysis confirmed the karyotypic analysis and established the deletion size to 7.7 Mb. Case 4 carried a translocation between chromosomes 14 and 22 [46, XY, der(22)-t(14;22)(q32.33;q13.31)]. Array CGH analysis revealed a 6.6 Mb deletion at 22q13.31qter. In case 7, a deletion of 5.0 Mb was identified, whereas in case 8 the deletion

spanned 3.9 Mb. The latter 22q13 deletion was associated with a duplication of 2.0 Mb, including 13 clones adjacent to the deleted region (Figure 2b). In addition to these subtelomeric copy number alterations, a duplication of ~330 kb on 22q11.1 was detected in the same patient. Duplications in the same region next to the centromere were identified in two other cases in this series (cases 4 and 7). In the control panel of 72 normal individuals tested by a tiling resolution genome-wide BAC array, copy number




Figure 2 Examples of chromosome- 22 profiles obtained by array CGH. Arrays contained 350 cloned chromosome- 22 genomic DNA targets (indicated by small circles representing the mean \log_2 -transformed and Lowess-normalised T/R intensity ratios), ordered from q11.1 to qter on the basis of physical mapping positions obtained from the May 2004 freeze of the UCSC Genome Browser. The centromere is indicated by a hatched area. A, case 1: del(22)(q13.2); B, case 8: del(22)(q13.31). Note the duplication of 2.0Mb on 22q13.31 and the duplication on 22q11.1.

gain of the same region was observed in five individuals, whereas loss of the chromosomal segment was seen in 21 controls (de Vries, submitted).

Discussion

For detailed analyses of patients with known 22q13 deletions, a tiling resolution array was constructed with a 1.7-fold coverage of the long arm of chromosome 22. Buckley *et al*¹² demonstrated the utility of such a comprehensive chromosome 22 array by profiling acral melanoma, dermatofibrosarcoma, DiGeorge syndrome, and neurofibromatosis 2. The chromosome 22 tiling resolution array had an average clone spacing of 100 kb, resulting in a resolution that is 30 times higher than high-resolution karyotyping. The array did not cover the most telomeric 635 kb of the chromosome, which includes the gene SHANK3/ProSAP2. Haploinsufficiency of this gene has been proposed to be responsible for the major neurological features of the 22q13 deletion syndrome.^{6,13,14} However, FISH analysis using subtelomeric clones, confirmed the extension of all deletions found till the subtelomeric region.

In the present study, a considerable difference in deletion sizes was noted, which is in accordance with the results of Luciani *et al*³ which showed an extremely variable 22qter deletion size, extending from 160 kb to 9 Mb. Interestingly,

a complex chromosome 22 rearrangement was observed in case 8, with a unique combination of a deletion and a duplication of 22q13. The detection of the deletion-duplication in this patient adds to a growing number of similar cases identified for other chromosomes, including deletion-duplications in 1p, 2q, 4p, and 8p.^{15–18} Giglio *et al*¹⁹ demonstrated that the formation of the inverted duplications of 8p associated with a terminal deletion is caused by nonallelic homologous recombination (NAHR) between two olfactory receptor-gene clusters. In addition, Ballif *et al* described two terminal deletions of 1p36 associated with cryptic interrupted inverted duplications. This type of chromosome rearrangement may be more common than previously thought. The detection of cryptic duplication associated with terminal deletions is greatly improved by high-resolution copy number screening using array CGH. Further studies are needed to determine the mechanisms underlying these rearrangements. Ballif *et al*¹⁸ proposed a premeiotic model in which a terminally deleted chromosome is generated in the germ line and passes through at least one breakage–fusion–bridge cycle in which uncapped sister chromatids are fused by nonhomologous end joining (NHEJ), resulting in gametes with terminal deletions associated with cryptic interrupted inverted duplications. The identification of recurrent proximal breakpoints in cases 2 and 3 (between RP11-786O06 and RP11-236I15) and cases 5 and 6 (between RP11-564B15 and RP11-673D06), suggests that these regions may be prone to recombination, due to the presence of yet unknown genome architectural features. Segmental duplications were present at or close to the recurrent breakpoints and also to the other, nonrecurrent breakpoints in our series. To a large extent, chromosome rearrangement breakpoints are located in intervals containing complex genomic architecture, such as AT-rich palindromes or low-copy repeats (LCRs).²⁰ Through the process of NAHR, LCRs can lead to translocations, inversions, duplications and interstitial deletions.²¹ However, the mechanisms for generating and/or stabilising terminally deleted chromosomes are poorly understood. NEHJ, possibly stimulated by LCRs or other repetitive sequences, may be one of the causative mechanisms for the terminal 22q13 deletions in our series.

In addition to the known 22qter deletions, a submicroscopic duplication on 22q11.1 next to the centromere was identified in three cases (cases 4, 7 and 8). In the control population of 72 normal individuals, copy number gains in the same region were identified in five individuals, whereas losses were observed in 21 controls (de Vries; submitted), indicating that this anomaly represents a LCV. This LCV at 22q11.1 was previously reported by Sebat *et al*²² (<http://projects.tcag.ca/variation/>) and stresses the variation of the human genome and the importance of parental and control analysis in case a submicroscopic alteration is identified.

Location	Cytoband	Clone	1	2	3	4	5	6	7	8	9
41 Mb	q13.2	RP11-420C16									
	q13.2	RP11-657N06									
	q13.2	RP11-744N13				EXCL					
	q13.2	RP11-415M09									EXCL
	q13.2	RP11-65114									
	q13.2	RP11-241G19		EXCL							EXCL
	q13.2	RP11-60H08	LOSS								
	q13.2	RP11-400M07	LOSS				EXCL				
	q13.2	RP11-804K19	LOSS								
	q13.2	RP11-582G11	LOSS								EXCL
42 Mb	q13.2	RP11-794G14				EXCL					
	q13.2	RP11-786O06	LOSS								
	q13.2	RP11-236I15	LOSS	LOSS	LOSS						
	q13.2	RP11-67I21	LOSS	LOSS	LOSS						
	q13.2	CTD-2010M18	EXCL	LOSS	LOSS				EXCL	EXCL	EXCL
	q13.2	RP11-50E02	LOSS	LOSS	LOSS	EXCL					
	q13.2	RP11-731M01	LOSS	LOSS	LOSS	EXCL					
	q13.2	RP11-80L20	LOSS	LOSS	LOSS						
	q13.31	RP11-535F10	LOSS	LOSS	LOSS	EXCL					
	q13.31	RP11-746K24	LOSS	LOSS	LOSS						
43 Mb	q13.31	RP11-792K05	LOSS	LOSS	LOSS						
	q13.31	RP11-135L16	LOSS	LOSS	LOSS	LOSS					
	q13.31	RP11-357F14	LOSS	LOSS	LOSS	EXCL					
	q13.31	RP11-41J01	LOSS	LOSS	EXCL	EXCL					
	q13.31	RP11-590C21	LOSS	LOSS	LOSS	LOSS					
	q13.31	CTD-2008L15	LOSS	LOSS	EXCL	EXCL					
	q13.31	RP11-766K21	LOSS	LOSS	LOSS	LOSS					
	q13.31	RP11-49A20	LOSS	LOSS	EXCL	EXCL	LOSS	LOSS			
	q13.31	RP11-673D06	LOSS	LOSS	LOSS	EXCL	LOSS	LOSS		GAIN	
	q13.31	RP11-660F09	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS		GAIN	
44 Mb	q13.31	RP11-23B21	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS		GAIN	
	q13.31	RP11-585K21	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS		GAIN	
	q13.31	RP11-379E18	LOSS	LOSS	LOSS	EXCL	LOSS	LOSS		GAIN	
	q13.31	RP11-192I08	LOSS	LOSS	LOSS	EXCL	LOSS	LOSS		GAIN	
	q13.31	RP11-699K18	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS		GAIN	
	q13.31	RP11-435J19	LOSS	EXCL	LOSS	LOSS	EXCL	LOSS	LOSS	GAIN	EXCL
	q13.31	RP11-953P12	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	GAIN	
	q13.31	RP11-704E16	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	GAIN	
	q13.31	RP11-313M05	LOSS	LOSS	LOSS	EXCL	LOSS	LOSS	LOSS	GAIN	
	q13.31	RP11-620A14	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	GAIN	
45 Mb	q13.31	RP11-234M14	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	GAIN	
	q13.31	RP11-427B17	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	
	q13.31	RP11-751L10	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	
	q13.31	RP11-506A05	LOSS	LOSS	EXCL	LOSS	LOSS	LOSS	LOSS	LOSS	EXCL
	q13.31	RP11-607P17	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	EXCL
	q13.31	RP11-5G12	LOSS	LOSS	LOSS	EXCL	LOSS	LOSS	LOSS	LOSS	
	q13.31	RP11-704G20	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	
	q13.31	RP11-720H05	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS
	q13.31	RP11-320G02	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS
	q13.31	RP11-689F11	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS
46 Mb	q13.32	RP11-328I12	LOSS	LOSS	EXCL	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS
	q13.32	RP11-799D02	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS
	q13.32	RP11-693J18	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS
	q13.32	RP11-690L04	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS
	q13.32	CTD-2260N21	LOSS	LOSS	EXCL	EXCL	LOSS	LOSS	EXCL	LOSS	LOSS
	q13.32	RP11-262A13	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS
	q13.32	RP11-53E22	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS
	q13.32	CTD-2006M09	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS
	q13.32	RP11-693A20	LOSS	LOSS	LOSS	EXCL	LOSS	LOSS	LOSS	LOSS	LOSS
	q13.32	RP11-242B05	LOSS	EXCL	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	EXCL
47 Mb	q13.32	RP11-636D02	LOSS	LOSS	EXCL	LOSS	LOSS	LOSS	LOSS	LOSS	EXCL
	q13.32	RP11-255N20	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	EXCL	LOSS	LOSS
	q13.33	RP11-12O20	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS
	q13.33	RP11-551M20	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS
	q13.33	RP11-687O19	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	EXCL
	q13.33	RP11-792P08	LOSS	LOSS	LOSS	EXCL	LOSS	LOSS	LOSS	LOSS	LOSS
	q13.33	RP11-314N05	LOSS	LOSS	LOSS	EXCL	LOSS	LOSS	LOSS	LOSS	LOSS
	q13.33	RP11-94B12	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS
	q13.33	RP11-329B15	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS
	q13.33	RP11-125K03	LOSS	LOSS	LOSS	EXCL	LOSS	LOSS	LOSS	LOSS	LOSS
48 Mb	q13.33	RP11-734K06	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS
	q13.33	RP11-232E17	LOSS	LOSS	LOSS	EXCL	LOSS	LOSS	LOSS	LOSS	LOSS
	q13.33	RP11-931F19	LOSS	LOSS	LOSS	LOSS	EXCL	LOSS	LOSS	LOSS	EXCL
	q13.33	RP11-428L10	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS	LOSS

Figure 3 Overview of the array CGH results for the nine patients with monosomy 22qter. Arrays contained 350 chromosome- 22 DNA BAC clones, ordered from q11.1 to qter on the basis of physical mapping positions obtained from the May 2004 freeze of the UCSC Genome Browser. The distal 9 Mb of the long arm of chromosome 22 is depicted in the figure. Copy number alterations were identified, using a Hidden Markov Model algorithm. Three hidden states represent normal (*empty*), loss (LOSS) and gain (GAIN) conditions. Individual clones that did not pass quality control criteria were excluded (EXCL).

In the current study, no relation between clinical features and deletion size could be observed. The clinical features observed were consistent with the common clinical phenotype associated with the 22q13 deletion syndrome,⁵ although dolichocephaly and ptosis were not found in the current study. Global developmental delay and absent or severely delayed speech were observed in all patients. Hypotonia was present in 89% of the cases (8/9). A pointed chin was present in cases 1 and 4–7. Wilson *et al*⁶ previously suggested a candidate gene for this feature in the proximal region of 22q13, however this could not be confirmed in our series. In addition, in case 8, ophthalmic assessment showed myopia and salt-and-pepper retinal changes suggestive of retinitis pigmentosa. These eye anomalies, which have not been reported in the 22q13 deletion syndrome before, are possibly attributable to the 2 Mb 22q13.31 duplication in this patient. Relationship between the deletion size and clinical features could not be observed. However, case 9 with the smallest 22q13 deletion (3.3 Mb), did not show any of the dysmorphic features commonly described in the 22q13 deletion syndrome. Facial dysmorphic features in this patient included upslanting palpebral fissures, a moderate hypertrophic nasal root, and thick lips.¹⁰ These findings underline the study of Wilson *et al*, in which no significant correlation with the size of the deletion could be demonstrated for most clinical features and support the idea that a gene in the 3.3 Mb minimal deleted region (notably SHANK3/PROSAP2) may be the major candidate gene in the 22q13 deletion syndrome.^{3–6}

In conclusion, this study underscores the utility of array CGH for further characterisation of the size and nature of subtelomeric deletions. In addition, these results confirm the considerable differences in deletion size observed in patients with the 22q13 deletion syndrome, regardless of the clinical phenotype.

Acknowledgements

We thank the patients and their parents for their cooperation. David A Koolen, Joris A Veltman and Bert BA de Vries were supported by a grant from The Netherlands Organisation for Health Research and Development.

References

- De Vries BB, Winter R, Schinzel A, Ravenswaaij-Arts C: Telomeres: a diagnosis at the end of the chromosomes. *J Med Genet* 2003; **40**: 385–398.
- Knight SJ, Flint J: Perfect endings: a review of subtelomeric probes and their use in clinical diagnosis. *J Med Genet* 2000; **37**: 401–409.
- Luciani JJ, de Mas P, Depetris D *et al*: Telomeric 22q13 deletions resulting from rings, simple deletions, and translocations: cytogenetic, molecular, and clinical analyses of 32 new observations. *J Med Genet* 2003; **40**: 690–696.
- Manning MA, Cassidy SB, Clericuzio C *et al*: Terminal 22q deletion syndrome: a newly recognized cause of speech and language disability in the autism spectrum. *Pediatrics* 2004; **114**: 451–457.
- Phelan MC, Rogers RC, Saul RA *et al*: 22q13 deletion syndrome. *Am J Med Genet* 2001; **101**: 91–99.
- Wilson HL, Wong AC, Shaw SR *et al*: Molecular characterisation of the 22q13 deletion syndrome supports the role of haploinsufficiency of SHANK3/PROSAP2 in the major neurological symptoms. *J Med Genet* 2003; **40**: 575–584.
- Veltman JA, Yntema HG, Lugtenberg D *et al*: High resolution profiling of X chromosomal aberrations by array comparative genomic hybridisation. *J Med Genet* 2004; **41**: 425–432.
- De Vries BB, Bitner-Glindzicz M, Knight SJ *et al*: A boy with a submicroscopic 22qter deletion, general overgrowth and features suggestive of FG syndrome. *Clin Genet* 2000; **58**: 483–487.
- Koolen DA, Nillesen WM, Versteeg MH *et al*: Screening for subtelomeric rearrangements in 210 patients with unexplained mental retardation using multiplex ligation dependent probe amplification (MLPA). *J Med Genet* 2004; **41**: 892–899.
- Goizet C, Excoffier E, Taine L *et al*: Case with autistic syndrome and chromosome 22q13.3 deletion detected by FISH. *Am J Med Genet* 2000; **96**: 839–844.
- Vissers LE, De Vries BB, Osoegawa K *et al*: Array-based comparative genomic hybridization for the genomewide detection of submicroscopic chromosomal abnormalities. *Am J Hum Genet* 2003; **73**: 1261–1270.
- Buckley PG, Mantripragada KK, Benetkiewicz M *et al*: A full-coverage, high-resolution human chromosome 22 genomic microarray for clinical and research applications. *Hum Mol Genet* 2002; **11**: 3221–3229.
- Anderlid BM, Schoumans J, Anneren G *et al*: FISH-mapping of a 100-kb terminal 22q13 deletion. *Hum Genet* 2002; **110**: 439–443.
- Bonaglia MC, Giorda R, Borgatti R *et al*: Disruption of the PROSAP2 gene in a t(12;22)(q24.1;q13.3) is associated with the 22q13.3 deletion syndrome. *Am J Hum Genet* 2001; **69**: 261–268.
- Cotter PD, Kaffe S, Li L, Gershin IF, Hirschhorn K: Loss of subtelomeric sequence associated with a terminal inversion duplication of the short arm of chromosome 4. *Am J Med Genet* 2001; **102**: 76–80.
- Florida G, Piantanida M, Minelli A *et al*: The same molecular mechanism at the maternal meiosis I produces mono- and dicentric 8p duplications. *Am J Hum Genet* 1996; **58**: 785–796.
- Bonaglia MC, Giorda R, Poggi G *et al*: Inverted duplications are recurrent rearrangements always associated with a distal deletion: description of a new case involving 2q. *Eur J Hum Genet* 2000; **8**: 597–603.
- Ballif BC, Yu W, Shaw CA, Kashork CD, Shaffer LG: Monosomy 1p36 breakpoint junctions suggest pre-meiotic breakage-fusion-bridge cycles are involved in generating terminal deletions. *Hum Mol Genet* 2003; **12**: 2153–2165.
- Giglio S, Broman KW, Matsumoto N *et al*: Olfactory receptor-gene clusters, genomic-inversion polymorphisms, and common chromosome rearrangements. *Am J Hum Genet* 2001; **68**: 874–883.
- Shaw CJ, Lupski JR: Implications of human genome architecture for rearrangement-based disorders: the genomic basis of disease. *Hum Mol Genet* 2004; **13** (Spec No 1): R57–R64.
- Stankiewicz P, Lupski JR: Molecular-evolutionary mechanisms for genomic disorders. *Curr Opin Genet Dev* 2002; **12**: 312–319.
- Gebat J, Lakshmi B, Troge J *et al*: Large-scale copy number polymorphism in the human genome. *Science* 2004; **305**: 525–528.